Vaximm AG's Phase 2a trial demonstrates that VXM01, an oral anti-VEGFR-2 vaccine, combined with avelumab shows a favorable safety profile in recurrent glioblastoma patients, with no serious adverse events attributed to VXM01.
DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.
The brain hemorrhage treatment market is projected to experience substantial growth through 2032, driven by an aging population and increasing prevalence of risk factors such as hypertension and traumatic brain injuries.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.